Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Ann Surg Oncol. 2021 Sep;28(9):4859-4866. doi: 10.1245/s10434-020-09498-z. Epub 2021 Jan 8.
Esophagectomy with lymph node dissection is a choice of additional treatment after noncurative endoscopic resection (ER) of T1N0 esophageal squamous cell carcinoma (ESCC). The efficacy and safety of esophagectomy in this situation remain unclear when compared with upfront esophagectomy.
We investigated the short- and long-term outcomes of 321 patients with clinical T1N0M0 ESCC who underwent curative esophagectomy, and compared the status of lymph node metastasis, surgical results, and the prognosis between the ER and non-ER groups.
The ER group consisted of 57 patients (17.8%), while the non-ER group consisted of 264 patients (82.2%). The incidence of lymph node metastasis was not significantly different between the ER (24.6%) and non-ER groups (30.7%), and there was no significant difference in surgical outcomes between the groups. The distribution of metastatic lymph nodes was very similar between the groups. However, 13 of 14 patients (93%) with lymph node metastasis in the ER group and 63 of 82 patients (77%) with lymph node metastasis in the non-ER group had pN1 disease, while the remaining 18 patients (23%) with lymph node metastasis in the non-ER group had pN2 or N3 disease. Overall and relapse-free survival rates were significantly better in the ER group than in the non-ER group (p < 0.05 and p < 0.01, respectively). To date, no patients in the ER group experienced disease recurrence.
Additional esophagectomy is a safe and effective treatment modality for patients after noncurative ER.
对于 T1N0 食管鳞癌(ESCC)患者,非治愈性内镜切除(ER)后进行淋巴结清扫的食管切除术是一种额外的治疗选择。与直接进行食管切除术相比,这种情况下食管切除术的疗效和安全性尚不清楚。
我们研究了 321 例临床 T1N0M0 ESCC 患者行根治性食管切除术的短期和长期结果,并比较了 ER 组和非 ER 组的淋巴结转移状态、手术结果和预后。
ER 组 57 例(17.8%),非 ER 组 264 例(82.2%)。ER 组(24.6%)和非 ER 组(30.7%)的淋巴结转移发生率无显著差异,两组间手术结果亦无显著差异。两组间转移淋巴结的分布非常相似。然而,ER 组 14 例(93%)淋巴结转移患者和非 ER 组 82 例(77%)淋巴结转移患者均为 pN1 疾病,而非 ER 组其余 18 例(23%)淋巴结转移患者为 pN2 或 N3 疾病。ER 组的总生存和无复发生存率明显优于非 ER 组(p<0.05 和 p<0.01)。迄今为止,ER 组无一例患者复发。
对于非治愈性 ER 后的患者,附加食管切除术是一种安全有效的治疗方法。